| der Anstieg kann auch nur durch ein Analysten Upgrade von Sell zu hold schon losgehen...bin gespannt, wie es hier weiter geht. Sequenom Inc. /quotes/comstock/15*!sqnm/quotes/nls/sqnm (SQNM 3.39, +0.41, +13.76%) was one bright spot, with shares climbing 14% to $3.40 after analysts at Lazard Capital Markets upgraded the stock to hold from sell. The analysts said that while Sequenom was still a risky investment, if the company's new Down syndrome test is successful, the stock could shoot up to more than $20 a share. The analysts added that the test may not be validated until early 2010. If the Downs test turns out to be unreliable, Sequenom shares could drop $1 to $2, they said. Qiagen hat gestern die Technologie gelauncht, RNA und DNA Fragment zu vervliefältiegn Venlo, The Netherlands, May 25, 2009 --- QIAGEN today announced the launch of a novel product for extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. Scientists consider these DNA and RNA fragments to have great potential for the highly sensitive and non-invasive diagnosis of a wide range of diseases, including congenital disorders, malignancies such as colon and lung cancer, and infections. The new QIAamp Circulating Nucleic Acid Kit is expected to significantly facilitate the corresponding biomarker research and the introduction of novel molecular tests in prenatal diagnostics which can replace risky, invasive procedures such as amniocentesis. Free circulating DNA and RNA fragments are found in body fluids such as plasma, serum and urine. Scientific research has demonstrated that plasma, in particular, carries a variety of nucleic acids from viruses and different tissues throughout the body, including developing fetuses and tumors. In cancer research, it has also been shown that the concentration of tumor DNA fragments is related to the extent of the disease. The analysis of such DNA and RNA fragments thus not only enables new, virtually non-invasive approaches to the early and highly sensitive detection of different malignancies such as colon or lung cancer, but can also help to monitor the progress of the disease and to assess patient outcomes. Likewise, fetal DNA and RNA fragments circulating in maternal blood can be used for the non-invasive molecular detection of congenital disorders in prenatal diagnostics, an area where QIAGEN also cooperates with Sequenom, Inc. which is a leader in this field. |
